The Trajectory of the Fecal Microbiome in Patients with Multidrug-Resistant Urinary Tract Infections
Urinary tract infections (UTIs) affect 150 million people a year worldwide and account for $3.5 billion dollars in healthcare and societal costs in the U.S. alone. UTIs of particular concern are those caused by multidrug-resistant organisms (MDROs), which consist of bacteria resistant to most available antibiotics and are often referred to as “superbugs.” Antibiotic resistance is critical public health issue, and it is estimated that MDRO infections will cause more deaths than cancer by 2050. Furthermore, it is estimated that by 2050, 10 million lives per year and a cumulative US$100 trillion of economic output are at risk due to MDROs.
UTIs are the most common type of MDRO infections, and up to 30% of patients with a first MDRO UTI experience a recurrence. UTIs are the most common type of infection in the elderly, and the elderly are at high risk for MDRO infections. The human gastrointestinal tract is a common source of MDRO UTIs, as the gut bacteria contaminate the outside of the urethra, then travel to the bladder to cause a UTI. In order to create methods to prevent MDRO infections and recurrence of infections, we propose a study to understand the fecal microbiome in patients with MDRO UTIs.
Our study has two main goals. The first is to understand changes in the fecal microbiome of patients that develop MDRO UTI. There are no studies of the fecal microbiome in patients with MDRO UTI, therefore this is a necessary step. We hypothesize that at the time of the acute infection, the MDRO causing the UTI will be present at a high concentration in the fecal microbiota. After appropriate treatment, we hypothesize that the MDRO concentration will decrease in the gut (as compared to the pre-treatment time-point), but will not be completely eliminated. Our second goal is to identify bacterial communities that are associated with recurrent MDRO UTIs. We hypothesize there are microbial communities in the gut that are associated an increased risk for recurrent UTI, and identification of these communities can be used to predict patients who will develop recurrent UTI. Once we understand the types of microbial communities that present in the fecal microbiota, we can then develop interventions to predict recurrent MDRO infections and future methods to prevent infection.
In this study, we will recruit patients with MDRO UTIs and utilize culture-based and metagenomic techniques to characterize the GI microbiome. Culture-based methods allow us to isolate the MDRO causing the UTI. Metagenomic techniques directly analyze bacterial DNA extracted from specimens, enabling a culture- independent understanding of the different type of microbial communities within a given environment. We will recruit patients with MDRO UTIs and obtain urine and stool specimens at multiple time points from the time of initial infection. At each time point, we will collect detailed information on symptoms, medical history, medication exposures, and dietary intake. We have already recruited 12 patients for this study, four of whom had recurrent UTIs, and collected 97 urine and 70 stool specimens from these subjects. Funding from the Longer Life Foundation (LLF) would allow for continued processing of specimens via microbiologic and metagenomic methods.
This study will address a critical barrier to progress in the field of MDRO infections, and improve our scientific knowledge by identifying the microbial communities associated with recurrent MDRO UTI. This study is significant to the insurance industry because we currently do not have methods to predict patients at risk for MDRO UTIs. If we are able to identify methods to predict recurrent UTIs, interventions can be taken to prevent fulminant infections and hospitalizations. With the increasing rates of morbidity and mortality associated with MDRO infections, this study will fill a knowledge gap that will ultimately improve patient care.